Breakthrough cancer pain - still a challenge

Area of Science:

• Oncology
• Pain Management
• Pharmacology

Background:

• Breakthrough cancer pain (BCP) is a transient exacerbation of otherwise controlled baseline pain in cancer patients.
• BCP prevalence is high, ranging from 33% to 95% across various cancer patient populations.
• Effective management requires an interdisciplinary and multimodal approach.

Purpose of the Study:

• To evaluate the efficacy and safety of a novel pectin-based intranasal fentanyl formulation for breakthrough cancer pain.
• To assess the formulation's suitability for rapid and convenient administration in clinical practice.

Main Methods:

• Utilized a pectin-based intranasal fentanyl formulation designed for rapid absorption.
• Focused on patient-reported pain relief and caregiver administration ease.
• Assessed the formulation's effectiveness in managing breakthrough cancer pain episodes.

Main Results:

• The intranasal fentanyl formulation demonstrated effectiveness in providing rapid analgesia.
• The pectin-based formulation exhibited a favorable toxicity profile.
• Convenient dosing and ease of administration by caregivers were noted advantages.

Conclusions:

• The pectin-based intranasal fentanyl formulation represents a significant advancement in managing breakthrough cancer pain.
• This formulation offers rapid, effective pain relief with a good safety profile.
• Its ease of administration enhances patient care, especially when patients cannot self-administer.